Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

Inclusion Criteria: * Patients must have histologically confirmed metastatic or recurrent solid tumor malignancy for which standard curative or palliative measures do not exist or are no longer effective * Dose escalation/phase I: Metastatic or recurrent solid tumors with measurable or evaluable disease * Dose expansion exploratory cohorts (nivolumab + ipilimumab + ZEN003694): Recurrent BRCAwt epithelial ovarian carcinoma patients who have progressed or recurred within \< 6 months from prior platinum-based therapy * Dose escalation and expansion exploratory cohorts: Patients must have measurable and biopsiable disease (at least two lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1. For patients in the dose escalation with evaluable disease, biopsy is mandated if feasible * No more than 5 lines of prior therapy for the dose escalation and expansion phases * In the expansion cohorts, up to 2 prior lines in the platinum-resistant setting is allowed * Patients with primary refractory ovarian cancer (who progressed while on primary 1L platinum therapy) will be excluded in the dose expansion cohorts but allowed in the dose escalation cohort * Patients who have had chemotherapy or radiotherapy more than 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study and who have recovered from adverse events due to agents administered more than 4 weeks earlier are eligible; for oral therapies, a patient is eligible after 5 hal…